News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Data on VIVUS, Inc. (VVUS)'s Qnexa To Be Featured at The Obesity Society Annual Meeting

10/5/2009 8:10:21 AM

MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.

"I am pleased that Dr. Day and Dr. Garvey can share the results of the phase 3 obesity studies and phase 2 obesity studies with our colleagues in the medical and pharmaceutical community," stated Leland Wilson, president and chief executive officer of VIVUS. "We are actively pursuing a comprehensive presentation and publication strategy, and are excited by the opportunity to communicate these data at Obesity Society's annual meeting. We look forward to additional presentations in the future with the ultimate goal of publication in a top-tier medical journal."

Following are details about the upcoming presentations:

27th Annual Scientific Meeting of The Obesity Society, October 24-28, 2009, Marriott Wardman Park Hotel, in Washington, DC

Date and Time: Saturday, October 24, 2009, 1:00 PM EDT

Session: Preconference

Presentation: Pharmacotherapy Update

Chairs: Ken Fujioka, MD, Louis J. Aronne, MD, and Richard Pratley, MD

Presenter: Wesley W. Day, PhD

Date and Time: Sunday, October 25, 2009, 5:30 PM EDT

Session: Pharmacotherapy

Presentation Title: "One-Year Treatment with Low Dose VI-0521 in Type 2 Diabetes Demonstrates Sustained Weight Loss and Continuous Glycemic Benefit"

Presenter: W. Timothy Garvey, MD

About Qnexa

Qnexa (Q-NEX-uh) is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. Qnexa, an investigational drug, is being developed to address weight loss. In phase 2 and 3 clinical data to date, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.


CONTACT: VIVUS, Inc., Timothy E. Morris, Chief Financial Officer,
+1-650-934-5200; Investor Relations: The Trout Group, Brian Korb,
+1-646-378-2923; or Media Relations: Pure Communications, Inc., Sheryl
Seapy, +1-949-608-0841

Web site:

Read at

comments powered by Disqus